Estrogen Use in Protection From Cognitive Decline

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00097058

Enrollment

Registered

2004-11-18

Start date

2003-08-31

Completion date

2014-11-30

Last updated

2014-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Menopause

Keywords

Aging, Menopause, Estrogen Replacement Therapy, Cognitive Decline

Brief summary

This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.

Detailed description

A total of 71 postmenopausal women ages 50-65 on estrogen therapy will be randomized to continue or discontinue use of estrogen and will be followed for two years. Participants will undergo PET and MRI scans and neuropsychological assessments initially and at the end of the two-year follow-up period. These procedures will allow us to evaluate brain metabolism and cognitive performance at baseline and two years following continuation or discontinuation of estrogen therapy. We hypothesize that women who discontinue estrogen will show more evidence of decline than those who continue estrogen. This project will expand current knowledge of effects of estrogen by 1) determining whether estrogen use among postmenopausal women at risk for cognitive decline is protective of brain metabolism, 2) identifying early predictors for cognitive decline, and 3) developing guidelines for estrogen use in postmenopausal women.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

45 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Women between the ages of 45 and 65 * Currently on hormone replacement * One year or more post complete cessation of menses * Willing to sign the Human Subject Protection Consent form prior to enrollment in the study * Willing to be randomized to continue or discontinue estrogen therapy * Adequately visually and auditorially acute to allow neuropsychological testing * Beyond 8 years of educational achievement to allow adequate neuropsychological testing * Willing to undergo brain imaging * At risk for cognitive decline, as defined by one or more of the following: Personal or family history of mood disorder, Hypothyroidism, Diabetes, Family history of Alzheimer's, APOE-4 allele

Exclusion criteria

* Diagnosis of possible or probable Alzheimer's disease or dementia * Cerebrovascular disease or uncontrolled hypertension (systolic BP \>170 or diastolic BP \>100) * History of myocardial infarction within previous year or unstable heart disease * History of significant liver disease, pulmonary disease, or current cancer * Contraindication for MRI (metal in body, claustrophobia, etc.)

Design outcomes

Primary

Measure	Time frame
Changes in cognition and brain metabolism	Baseline and 24 months

Countries

United States

Outcome results